Asset Management One Co., Ltd. Alkermes Plc. Transaction History

Asset Management One Co., Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$13.06 - $21.24 $207,001 - $336,654	-15,850 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$17.29 - $21.74 $1.07 Million - $1.34 Million	-61,864 Reduced 79.6%	15,850 $323,000
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $207,679 - $361,093	9,673 Added 14.22%	77,714 $1.75 Million
Q1 2019 May 15, 2019	SELL	$28.4 - $36.49 $4.72 Million - $6.06 Million	-166,143 Reduced 70.95%	68,041 $2.48 Million
Q4 2018 Feb 13, 2019	BUY	$27.94 - $44.61 $23,469 - $37,472	840 Added 0.36%	234,184 $6.9 Million
Q3 2018 Nov 14, 2018	BUY	$38.6 - $46.12 $37,519 - $44,828	972 Added 0.42%	233,344 $9.91 Million
Q2 2018 Aug 14, 2018	BUY	$40.56 - $51.36 $2,028 - $2,568	50 Added 0.02%	232,372 $9.56 Million
Q1 2018 May 14, 2018	BUY	$53.61 - $67.26 $567,140 - $711,543	10,579 Added 4.77%	232,322 $13.5 Million
Q4 2017 Feb 14, 2018	SELL	$47.69 - $55.39 $602,515 - $699,797	-12,634 Reduced 5.39%	221,743 $12.1 Million
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $11.3 Million - $12.6 Million	230,745 Added 6353.11%	234,377 $11.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	3,632	3,632 $210,000

358

181M

168K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.66B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Asset Management One Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Asset Management One Co., Ltd. with notifications on news.